REFRACTORY MULTIPLE MYELOMA

This study tested whether taking a daily pill called lenalidomide after a stem cell transplant could help patients with multiple myeloma live longer without their cancer getting worse. About 460 patients who had their own stem cells transplanted were randomly assigned to receive …

This study is testing whether the drug vismodegib can help control advanced cancers that have specific genetic mutations and have stopped responding to standard treatments. The trial includes 35 adults with solid tumors, lymphoma, or multiple myeloma that have spread or are resis…

This study is testing a combination of four existing drugs (daratumumab, clarithromycin, pomalidomide, and dexamethasone) for people with multiple myeloma whose cancer has returned or stopped responding to prior treatment. The goal is to see if this specific mix can better contro…

This study is testing whether a pill called crizotinib can help control advanced cancers that have stopped responding to other treatments. It is specifically for patients whose tumors have a particular change in a gene called MET. Participants take the pill twice daily to see if …

This study is testing whether a drug called copanlisib can help control advanced cancers that have stopped responding to other treatments. It is specifically for patients whose cancer has a specific change in a gene called PTEN. The drug is given through an IV and aims to block s…

This study is testing an experimental pill called GSK2636771 for people with advanced cancers that have stopped responding to other treatments and have a specific genetic change called a PTEN mutation. The pill is designed to block a protein that these cancer cells may need to gr…

This study is testing a pill called trametinib for people with advanced cancers that have stopped responding to other treatments and have specific changes in a gene called BRAF. The pill aims to block proteins that these cancer cells need to grow. Researchers want to see if the t…

This study is testing whether a drug called copanlisib can shrink or stop the growth of advanced cancers that have a specific genetic change called a PIK3CA mutation. The drug works by blocking a protein that cancer cells need to grow. The trial includes 35 adults with various ad…

This trial is testing whether the drug afatinib can help control advanced cancers that have stopped responding to standard treatments. It is specifically for patients whose tumors have a specific genetic change (mutation) in a gene called EGFR, but who do not have lung cancer. Th…

This study is testing if an oral drug called MLN0128 can help control advanced cancers that have a specific genetic change (mTOR mutation) and have stopped responding to other treatments. About 35 patients with various advanced cancers, including solid tumors, lymphoma, or myelom…

This study is testing a drug called trametinib for people with advanced cancers that have a specific genetic change called an NF1 mutation. The drug works by blocking proteins that these cancer cells may need to grow. Researchers want to see if trametinib can shrink these tumors …

This study is testing a targeted drug called erdafitinib in patients with advanced cancers that have a specific genetic change (FGFR amplification). The drug works by blocking a faulty protein that tells cancer cells to grow. The trial aims to see if the drug can shrink tumors or…

This study is testing a new, personalized method for treating multiple myeloma that has returned or stopped responding to standard drugs. Doctors take a sample of a patient's cancer cells and test many different drugs on them in the lab to see which ones work best. The goal is to…

This early-stage trial is testing a new three-drug combination for people with multiple myeloma that has come back or stopped responding to previous treatments. The main goal is to find the safest and most effective dose of a new experimental drug, CB-839, when given with two exi…

This study is testing if the drug trametinib can help control advanced cancers that have specific genetic changes called GNAQ or GNA11 mutations. It is for patients with various cancers, including solid tumors and lymphomas, that have not responded to other treatments. The goal i…

This early-stage study is testing a new combination treatment for multiple myeloma that has come back or stopped responding to other therapies. It combines a lab-modified version of a patient's own immune cells (called TiNK cells) with a drug called isatuximab, along with standar…

This study is testing a combination of four medications for people with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to see if this drug combination can effectively control the cancer and extend the time patients live without their di…

This study is testing a new combination of drugs for people with multiple myeloma, a blood cancer, that has come back and stopped responding to standard treatments. The main goals are to find the safest dose of the new drug selinexor when combined with other cancer drugs, and to …

This is an early-stage study to check the safety of a new treatment called anti-BCMA CAR-T cell therapy for people with multiple myeloma that has come back or stopped responding to other drugs. Doctors will collect a patient's own immune cells, modify them in a lab to better targ…

This trial is testing whether the drug crizotinib can help control advanced cancers that have a specific genetic change called MET amplification. It is for adults with solid tumors, lymphoma, or multiple myeloma that have stopped responding to other treatments. The drug works by …

This study is testing if a drug called MLN0128 can help control advanced cancers that have specific genetic changes (TSC1 or TSC2 mutations). The drug works by blocking enzymes that cancer cells need to grow. It is for adults with solid tumors, lymphoma, or multiple myeloma that …

This study is testing whether a drug called afatinib can help people with advanced cancers that have a specific genetic change called a HER2 mutation. The drug works by blocking a protein that helps cancer cells grow. Researchers are enrolling about 40 patients whose cancers have…

This study is testing whether the drug sunitinib can help control advanced cancers that have a specific mutation in a gene called cKIT. The drug works by blocking the faulty signal from this mutated gene that tells cancer cells to grow. It is for a small group of patients (about …

This study is testing whether two drugs, dabrafenib and trametinib, can shrink or stop the growth of advanced cancers that have a specific genetic change called a BRAF V600 mutation. It is for patients with solid tumors, lymphoma, or multiple myeloma that have not responded to ot…

This study is testing a drug called defactinib in people with advanced cancers that have stopped responding to other treatments and have a specific genetic change called an NF2 mutation. The drug aims to block a protein that these cancer cells may need to grow. Researchers want t…

This large national trial is testing whether choosing cancer drugs based on the specific genetic changes found in a patient's tumor is more effective than standard approaches. It is for adults with advanced solid tumors, lymphoma, or multiple myeloma that have progressed after at…

This trial is testing whether the drug osimertinib can help control advanced cancers that have specific changes (mutations) in a gene called EGFR. The drug works by blocking the faulty protein these mutations create, which may slow or stop cancer growth. The study is for adults w…

This study is testing an experimental drug called taselisib for people with advanced cancers that have a specific genetic change called a PIK3CA mutation. The drug aims to block a protein that helps cancer cells grow, with the goal of shrinking tumors or stopping their growth. It…

This study is testing a combination of four drugs (selinexor, bortezomib, dexamethasone, and daratumumab) for people with multiple myeloma that has come back or stopped responding to other treatments. The goal is to see if this new combination can help control the cancer. About 6…

This trial is testing an oral drug called ulixertinib in patients with advanced cancers that have specific, less common changes in a gene called BRAF. The drug aims to block signals that tell cancer cells to grow, potentially slowing or stopping the disease. It is for patients wi…

This study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…

This study is testing if the drug crizotinib can shrink or stop the growth of advanced cancers that have a specific genetic change called an ALK rearrangement. It is for people with various solid tumors or blood cancers (excluding certain lung cancers and lymphomas) that have not…

This study is testing whether the drug crizotinib can shrink or stop the growth of advanced cancers that have a specific genetic change called a ROS1 translocation. The trial is for patients with various hard-to-treat cancers (like certain solid tumors, lymphomas, or myeloma) tha…

This trial is testing a targeted drug called ado-trastuzumab emtansine for patients with advanced cancers that have a specific genetic change called HER2 amplification. The drug is designed to find cancer cells with the HER2 marker and deliver chemotherapy directly to them. The s…

This study is testing a drug called binimetinib in patients with advanced cancers that have a specific genetic change called an NRAS mutation. The drug works by blocking proteins that cancer cells with this mutation need to grow. Researchers want to see if the drug can shrink the…

This trial is testing whether a pill called ipatasertib can help control advanced cancers that have stopped responding to other treatments and have a specific genetic change called an AKT mutation. About 35 patients with various advanced cancers, including solid tumors, lymphoma,…

This study is testing whether the drug AZD5363 can help control advanced cancers that have a specific genetic change called an AKT mutation. The trial includes 35 patients with various cancers (solid tumors, lymphoma, or myeloma) that have stopped responding to standard treatment…

This study is testing whether the drug AZD1775 can shrink or stop the growth of advanced cancers that have specific genetic changes called BRCA1 or BRCA2 mutations. The drug works by blocking a protein called WEE1 that these cancer cells may need to survive. The trial will involv…

This study is testing an experimental pill called GSK2636771 for people with advanced cancers that have stopped responding to other treatments. The drug is specifically for cancers that have completely lost a protein called PTEN. Researchers want to see if the pill can shrink the…

This trial is testing how well the drug larotrectinib works for people with advanced cancers that have a specific genetic change called an NTRK fusion. The drug is designed to block the abnormal protein made by this gene change, which may slow or stop cancer growth. The study is …

This observational study aims to understand how doctors in Italy currently treat patients with advanced multiple myeloma that has stopped responding to standard medications. Researchers will collect existing medical records from about 250 adult patients to analyze treatment appro…